# Viridian Therapeutics (VRDN) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/VRDN
## Company Profile
- Ticker: VRDN
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Immunology, Ophthalmology
## Stock Data
- Close: 18.22 USD
- Market cap: 1752487313.34 USD
- Last updated: 2026-10-06
## Business Overview
### Autoimmune and Rare-Disease Biotechnology Company
Viridian Therapeutics develops antibody medicines for serious autoimmune and rare diseases. Its portfolio combines commercial-stage thyroid eye disease exposure with follow-on programs intended to improve dosing convenience or address related disease biology.
### Lumvoa Thyroid Eye Disease Franchise
Lumvoa, or veligrotug, is an IGF-1 receptor antibody for thyroid eye disease. Following U.S. approval and launch, Viridian is building a specialty commercial organization focused on ophthalmologists, endocrinologists, and the centers that manage active thyroid eye disease.
### Elegrobart Subcutaneous Program
Elegrobart is a subcutaneous IGF-1 receptor antibody designed for patient-administered dosing through an autoinjector. The program is intended to offer an alternative to infusion-based treatment and is supported by the Phase 3 REVEAL development program.
### TSH Receptor Antibody Expansion
Viridian is developing an antibody against the thyroid-stimulating hormone receptor for Graves' disease and potentially thyroid eye disease. The program targets an upstream driver of thyroid autoimmunity rather than focusing only on downstream tissue effects.
### FcRn Pipeline
VRDN-008 and VRDN-006 are FcRn-targeting programs designed to reduce pathogenic immunoglobulin G antibodies. These assets broaden the company into additional antibody-mediated diseases and provide both clinical-stage and follow-on opportunities beyond thyroid disorders.
## Why The Stock Is Moving

As of Oct 6, 2026, VRDN closed down 4.11% at $18.22. No new same-company headline was identified in the current news window.

## Future Catalysts

- Submission of the elegrobart biologics license application in the first quarter of 2027.
- Investigational new drug submission for the TSH receptor antibody program in the fourth quarter of 2026.
- Phase 1 healthy-volunteer data for VRDN-008 in the second half of 2026.

## Recent News
- 2022-04-06 12:00 EST — [Viridian Therapeutics to Participate in The 21st Annual Needham Virtual Healthcare Conference on April 14](https://biopharmsignal.com/news/VRDN/viridian-therapeutics-to-participate-in-the-21st-annual-needham-virtual-healthca-108c221d) — Source: Viridian Therapeutics
- 2022-04-04 20:05 EST — [Viridian Therapeutics Secures Flexible Credit Facility for Up to $75 Million From Hercules Capital](https://biopharmsignal.com/news/VRDN/viridian-therapeutics-secures-flexible-credit-facility-for-up-to-75-million-from-747e1dc0) — Source: Viridian Therapeutics
- 2022-03-21 20:05 EST — [Viridian Therapeutics Doses First Subject in First-in-Human Clinical Trial Evaluating VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease](https://biopharmsignal.com/news/VRDN/viridian-therapeutics-doses-first-subject-in-first-in-human-clinical-trial-evalu-f60b07d3) — Source: Viridian Therapeutics
- 2022-03-14 20:05 EST — [Viridian Therapeutics to Participate in 32nd Annual Oppenheimer Healthcare Conference on March 15](https://biopharmsignal.com/news/VRDN/viridian-therapeutics-to-participate-in-32nd-annual-oppenheimer-healthcare-confe-9db95b4d) — Source: Viridian Therapeutics
- 2022-03-10 21:05 EST — [Viridian Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results And Provides Corporate Updates](https://biopharmsignal.com/news/VRDN/viridian-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-result-50ad5708) — Source: Viridian Therapeutics